BioVie Inc. (BIVI) stock
BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
$0.94−0.05 (-5.27%)
Close on Nov 18, 2026Market cap $7.11MP/E –Yield –
BioVie operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioVie's operating income for the twelve months ending Jun 30, 2026 was -$22.65M. For fiscal 2026 it was -$22.65M. The highest annual figure on record is -$233.38K in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$22.65M | – |
| FY2025 | Jun 30, 2025 | -$18.07M | – |
| FY2024 | Jun 30, 2024 | -$32.18M | – |
| FY2023 | Jun 30, 2023 | -$45.08M | – |
| FY2022 | Jun 30, 2022 | -$27.25M | – |
| FY2021 | Jun 30, 2021 | -$138.05M | – |
| FY2020 | Jun 30, 2020 | -$2.69M | – |
| FY2019 | Jun 30, 2019 | -$2.50M | – |
| FY2018 | Jun 30, 2018 | -$2.37M | – |
| FY2017 | Jun 30, 2017 | -$1.55M | – |
| FY2016 | Jun 30, 2016 | -$432.03K | – |
| FY2015 | Jun 30, 2015 | -$233.38K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$5.72M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$5.39M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$6.26M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$5.28M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$3.66M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$2.99M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$7.29M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$4.12M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$4.79M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$7.73M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$8.78M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$10.88M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$10.98M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$13.77M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$11.49M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$8.83M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$9.29M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$5.75M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$6.67M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$5.55M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$131.60M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.00M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$3.06M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$386.76K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$576.97K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$699.25K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$710.45K | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$706.22K | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$655.99K | – |
| Q1 FY2019CQ3 2018 | Dec 31, 2018 | -$992.30K | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$523.91K | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$691.22K | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$494.81K | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$662.23K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$443.93K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$400.53K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$357.80K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$351.35K | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$269.62K | – |
See a number that looks wrong?